SCHEMBL19557971

SCHEMBL19557971

CSC(C)OCCN1CCCN(C)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHKA P35790 3/20 0.36
▸ SIGMAR1 Q99720 3/20 0.35
▸ HTR7 P34969 1/20 0.35
▸ CA2 P00918 1/20 0.34
▸ NCF1 P14598 1/20 0.34
▸ PRMT6 Q96LA8 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ HRH3 Q9Y5N1 3/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ SLC22A1 O15245 1/20 0.33
▸ CHRM2 P08172 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ ADRA2A P08913 1/20 0.33
▸ CHRM1 P11229 1/20 0.33
▸ DRD1 P21728 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25497382 0.93 ALDH1A1 (0.34) SIGMAR1KDM4EHRH3DRD3
SCHEMBL15316722 0.82 CHKA (0.40) CHKASIGMAR1HTR7CA2NCF1
SCHEMBL21941251 0.76 MEN1 (0.44) KDM4EHRH3KCNH2
SCHEMBL10192139 0.74 KDM1A (0.39) SIGMAR1KDM4E
SCHEMBL4808739 0.73 PSMB1 (0.44) KDM4EHRH3CYP1A2CYP3A4CYP2D6
SCHEMBL25492954 0.72 HRH3 (0.43) CHKASIGMAR1HTR7HRH3DRD3
SCHEMBL14500230 0.72 KDM4E (0.51) CHKASIGMAR1CA2NCF1PRMT6
SCHEMBL2916819 0.72 CHKA (0.43) CHKASIGMAR1HTR7CA2NCF1
SCHEMBL10196944 0.72 PSMB1 (0.41) SIGMAR1KDM4ECYP1A2CYP3A4CYP2D6
SCHEMBL27250180 0.71 CHKA (0.52) CHKASIGMAR1HTR7CA2NCF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9809590-B2 Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors ARRAY BIOPHARMA INC. (US) 2017-11-07 — — US disclosed
Send feedback